Tolerogenic Lipid Nanoparticles for Delivering Self-Antigen mRNA for the Treatment of Experimental Autoimmune Encephalomyelitis.

MLA

Gomi, Masaki, et al. “Tolerogenic Lipid Nanoparticles for Delivering Self-Antigen MRNA for the Treatment of Experimental Autoimmune Encephalomyelitis.” Pharmaceuticals (14248247), vol. 16, no. 9, Sept. 2023, p. 1270. EBSCOhost, https://doi.org/10.3390/ph16091270.

APA

Gomi, M., Nakayama, Y., Sakurai, Y., Oyama, R., Iwasaki, K., Doi, M., Liu, Y., Hori, M., Watanabe, H., Hashimoto, K., Tanaka, H., Tange, K., Nakai, Y., & Akita, H. (2023). Tolerogenic Lipid Nanoparticles for Delivering Self-Antigen mRNA for the Treatment of Experimental Autoimmune Encephalomyelitis. Pharmaceuticals (14248247), 16(9), 1270. https://doi.org/10.3390/ph16091270

Chicago

Gomi, Masaki, Yuka Nakayama, Yu Sakurai, Ryotaro Oyama, Koki Iwasaki, Mizuki Doi, Yi Liu, et al. 2023. “Tolerogenic Lipid Nanoparticles for Delivering Self-Antigen MRNA for the Treatment of Experimental Autoimmune Encephalomyelitis.” Pharmaceuticals (14248247) 16 (9): 1270. doi:10.3390/ph16091270.